1. Scrip
  2. >>Business

CEO Exit Adds To Iovance Woes After Cell Therapy Setback

Filing Set Back Until 2022

 
• By Andrew McConaghie

Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.

Iovance Philadelphia Navy Yard rendering
The company's GMP cell therapy manufacturing facility in Navy Yard, Philadelphia is expected to be completed this year. • Source: DIGSAU

Iovance Biotherapeutics has suffered a double blow to its prospects, with a further delay to the filing of its first-in-class tumor-infiltrating lymphocyte (TIL) therapy and the resignation of CEO Maria Fardis.

The San Carlos, CA-based biotech is at the forefront of developing TILs, one of the most promising cell therapies being...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.

In Brief: Bavarian Nordic’s Board Votes For Private Equity Takeout

 
• By Joseph Haas

The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.

More from Scrip

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?